These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1830013)

  • 21. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia.
    Dunaif A; Graf M; Mandeli J; Laumas V; Dobrjansky A
    J Clin Endocrinol Metab; 1987 Sep; 65(3):499-507. PubMed ID: 3305551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glucose action and adrenocortical biosynthesis in women with polycystic ovary syndrome.
    Farah-Eways L; Reyna R; Knochenhauer ES; Bartolucci AA; Azziz R
    Fertil Steril; 2004 Jan; 81(1):120-5. PubMed ID: 14711554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries.
    Robinson S; Henderson AD; Gelding SV; Kiddy D; Niththyananthan R; Bush A; Richmond W; Johnston DG; Franks S
    Clin Endocrinol (Oxf); 1996 Mar; 44(3):277-84. PubMed ID: 8729522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance.
    Sepilian V; Nagamani M
    J Clin Endocrinol Metab; 2005 Jan; 90(1):60-5. PubMed ID: 15483106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Divergent correlations of circulating dehydroepiandrosterone sulfate and testosterone with insulin levels and insulin receptor binding.
    Schriock ED; Buffington CK; Hubert GD; Kurtz BR; Kitabchi AE; Buster JE; Givens JR
    J Clin Endocrinol Metab; 1988 Jun; 66(6):1329-31. PubMed ID: 2967305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
    Morales AJ; Laughlin GA; Bützow T; Maheshwari H; Baumann G; Yen SS
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue insulin sensitivity and body weight in polycystic ovary syndrome.
    Marsden PJ; Murdoch AP; Taylor R
    Clin Endocrinol (Oxf); 2001 Aug; 55(2):191-9. PubMed ID: 11531925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can the source of hyperandrogenism in adolescents with polycystic ovary syndrome predict metabolic phenotype?
    Al Nofal A; Viers LD; Javed A
    Gynecol Endocrinol; 2017 Nov; 33(11):882-887. PubMed ID: 28649885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin and insulin-like growth factor-I responsiveness in polycystic ovarian syndrome.
    Buyalos RP; Geffner ME; Bersch N; Judd HL; Watanabe RM; Bergman RN; Golde DW
    Fertil Steril; 1992 Apr; 57(4):796-803. PubMed ID: 1555690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin resistance and secretion in polycystic ovarian disease.
    Bruno B; Poccia G; Fabbrini A
    J Endocrinol Invest; 1985 Oct; 8(5):443-8. PubMed ID: 2934464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polycystic ovarian disease: the adrenal connection.
    Marouliss GB; Triantafillidis IK
    Pediatr Endocrinol Rev; 2006 Jan; 3 Suppl 1():205-7. PubMed ID: 16641861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.
    Ciaraldi TP; Aroda V; Mudaliar SR; Henry RR
    Metabolism; 2013 Nov; 62(11):1587-96. PubMed ID: 23958241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulin resistance in polycystic ovary syndrome.
    Shoupe D; Kumar DD; Lobo RA
    Am J Obstet Gynecol; 1983 Nov; 147(5):588-92. PubMed ID: 6227251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome.
    White D; Leigh A; Wilson C; Donaldson A; Franks S
    Clin Endocrinol (Oxf); 1995 May; 42(5):475-81. PubMed ID: 7621565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma androgens and oestradiol during oral glucose tolerance test in patients with polycystic ovaries.
    Tiitinen A; Pekonen F; Stenman UH; Laatikainen T
    Hum Reprod; 1990 Apr; 5(3):242-5. PubMed ID: 2191000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin, C-peptide, androgens, and beta-endorphin response to oral glucose in patients with polycystic ovary syndrome.
    Tropeano G; Lucisano A; Liberale I; Barini A; Vuolo IP; Martino G; Menini E; Dell'Acqua S
    J Clin Endocrinol Metab; 1994 Feb; 78(2):305-9. PubMed ID: 8106616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
    Li X; Lin JF
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Case report: amelioration of insulin resistance in diabetes with dehydroepiandrosterone.
    Buffington CK; Pourmotabbed G; Kitabchi AE
    Am J Med Sci; 1993 Nov; 306(5):320-4. PubMed ID: 8238089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dyslipidaemia in polycystic ovarian syndrome: different groups, different aetiologies?
    Meirow D; Raz I; Yossepowitch O; Brzezinski A; Rosler A; Schenker JG; Berry EM
    Hum Reprod; 1996 Sep; 11(9):1848-53. PubMed ID: 8921052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polycystic ovary syndrome: obesity, insulin resistance, hyperandrogenism.
    Lo Dico G; Alongi G; Savatteri L; Rini GB; Mascellino MR; Di Fede G; Rizzo G
    Acta Eur Fertil; 1989; 20(5):309-13. PubMed ID: 2700062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.